biotech
Life Sciences
Life Sciences enterprises contend with escalating R&D costs and regulatory silos.
Life Sciences enterprises contend with escalating R&D costs and regulatory silos that fragment clinical trials, lab data, and compliance workflows, stalling innovation amid AI-driven demands and global scrutiny. Disconnected EDC, LIMS, and pharmacovigilance systems delay trials by months, with daily development setbacks costing $500,000-$800,000 in lost revenue plus $40,000 in expenses source, while average drug-to-market costs exceed $2 billion. Deloitte's 2026 Life Sciences Outlook identifies siloed tech stacks and regulatory pressures as top barriers to productivity, with 41% of biopharma executives prioritizing R&D efficiency amid pricing and geopolitical headwinds. Source
engineering OUR APPROACH
- › We engineer sustainable IT solutions for precise execution from day one, unifying life sciences operations for compliant, accelerated R&D through specialised IT capabilities.
- › Workflow orchestration engine: Cloud-native systems automate trial protocols, patient matching, and site activation across global phases.
- › Role-optimized interfaces: CRA dashboards for monitoring, compliance portals for audits, executive analytics for pipeline forecasting, all GxP-validated.
- › Regulatory compliance fabric: Embedded engines enforce FDA 21 CFR Part 11, EMA Annex 11, and PV standards with automated validation.
- › Unified data platform: Harmonizes EDC, lab results, real-world evidence, and genomics into secure, federated repositories for analytics and ML governance.
trending_up IMPACTS
- ›Life sciences firms achieve transformative efficiency and compliance through technology intervention in their day-to-day operations:
- ›R&D timeline acceleration: Digital platforms compress clinical cycles 20-30%, slashing recruitment delays. Source
- ›Cost reduction through automation: Integrated systems cut operational expenses 15-30% via streamlined processes. Source
- ›Compliance risk mitigation: Automated trails reduce audit findings 35%+ under strict regulations. Source
- ›Innovation uplift: AI-ready data boosts trial success rates 15-20%, enhancing asset value. Source